National agency pushback against EMA fast track continues
31 March 2017
Germany’s healthcare cost watchdog is continuing to push back against the European Medicines Agency’s (EMA) plans to accelerate the approval of new medicines. The German institute worries fast-track drug approvals based on limited clinical trial data or real-world evidence will become the norm—and that this will undermine attempts to gauge the true safety and efficacy of medicines.
Brexit: Why U.K. life science is optimistic in the face of threats to R&D, funding
30 March 2017
In the run-up to the United Kingdom’s referendum on European Union membership, leaders from Big Pharmas, biotechs, academic groups and regulatory agencies based across the region warned repeatedly of the risks of Brexit. Now, two years out from the scheduled EU exit date, the tenor of the debate has shifted. Uncertainty and concerns remain, but the life science sector is increasingly confident about its post-Brexit prospects.
The World Laboratory Market is $108.5 Billion Market and Growing
30 March 2017
The global market for clinical laboratory services reached $108.5 billion for 2016, according to a new report from Kalorama Information. In addition to diagnosing patients, medical lab testing is performed to evaluate disease progression, monitor drug treatment and conditions, and determine individual therapy, among other reasons.
Why wait? Trump mounts an early raid on NIH’s ’17 budget in search of some spending money
30 March 2017
President Trump is looking for some extra cash this year. And to get it he’s ready to start slashing NIH funding now, rather than wait until the next budget year gets started.
New Study Demonstrates the Importance of Long-Term Funding for Cancer Research
29 March 2017
New drugs to treat cancer that are now emerging are the end products of research begun in the 1970s and '80s, a new study by Bentley University has found, demonstrating the importance of long-term research in bringing new therapies to market. The research, published in the journal PLOS One, appears as Congress considers deep cuts to the National Institutes of Health, whose budget funds research into cancer and other diseases.
Russian pharmaceutical market grew by 7.84% in 2016
29 March 2017
In 2016, the volume of the Russian pharmaceutical market increased by 7.84% in end-consumer prices compared to 2015 and reached 1.21 trillion rubles, according to the information prepared by the Ministry of Industry and Trade for the meeting of its Board.
MIPT research may help look for new drugs
27 March 2017
Scientists at MIPT, one of Russia’s leading tech universities in Moscow, have developed a method of simulating cellular membrane response to drug and toxin molecules, a way of analyzing drugs’ impact on human cells prior to administering the drugs, and studying ageing mechanisms without any experiments.
A pharmaceutical cluster is established in Moscow region
27 March 2017
The agreement was signed by IBPM of RAS, IPCP of RAS, ITEB of RAS, IFPB of RAS, BIBC of RAS, Hospital of ChSC of RAS, Hospital of PSC of RAS, Test Pushchino LLC, and Pre-Clinical Trials LLC. The agreement implies the integration of the competences of participants for development and trials of medicinal products.
Pharma's rep with patient groups was on the rise, but not anymore: PatientView
24 March 2017
It may have been too good to last. After an upswing in pharma's global reputation in 2015, its standing among patient groups has swung the other way—again. Only 38% of patient groups said the industry had either an “excellent” or “good” reputation, down from almost 45% last year.
Three considerations for the pharma industry as President Trump focuses on drug pricing
24 March 2017
As a presidential candidate, President Donald Trump repeatedly decried drug prices, suggesting that Americans should be allowed to purchase the products from abroad and that Medicare should be allowed to negotiate their prices. As president, he has continued to talk about drug pricing. Addressing Congress on Feb. 28, Trump said he would “work to bring down the artificially high cost of drugs, and bring them down immediately.”
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024